Capecitabine
- Generic Name
- Capecitabine
- Brand Names
- Ecansya, Xeloda, Capecitabine Medac, Ecansya (previously Capecitabine Krka), Capecitabine Accord, Capecitabine Teva
- Drug Type
- Small Molecule
- Chemical Formula
- C15H22FN3O6
- CAS Number
- 154361-50-9
- Unique Ingredient Identifier
- 6804DJ8Z9U
- Background
Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.
- Indication
Capecitabine is indicated as treatment for a variety of cancer types. For colorectal cancer, capecitabine is indicated as a single agent or a component of a combination chemotherapy regiment for the adjuvant treatment of stage III colon cancer and treatment unresectable or metastatic colorectal cancer. It can also be used as a part of a combination chemotherapy perioperative treatment of adult locally advanced rectal cancer. For breast cancer, capecitabine is indicated for advanced or metastatic breast cancer as a single agent if an anthracycline- or taxane-containing chemotherapy is not indicated or as a regimen with docetaxel after disease progression on prior anthracycline-containing chemotherapy. For gastric, esophageal, or gastroesophageal junction (GEJ) cancer, capecitabine is indicated as a component of a combination chemotherapy treatment for the treatment of adult unresectable or metastatic gastric, esophageal, or GEJ cancer or adult HER2-overexpressing metastatic gastric or GEJ adenocarcinoma who have not received prior treatment for metastatic disease. Finally, for pancreatic cancer, capecitabine is indicated as adjuvant treatment for adult pancreatic adenocarcinoma as a component of a combination chemotherapy regimen.
- Associated Conditions
- Advanced or Metastatic Breast Cancer, Carcinoma of Gallbladder, Cholangiocarcinoma, Hepatocellular Carcinoma, Locally Advanced Rectal Cancer (LARC), Metastatic Adenocarcinoma of the Gastroesophageal Junction, Metastatic Gastric Cancers, Metastatic Neuroendocrine Tumors, Pancreatic Adenocarcinoma, Pancreatic Cancer, Advanced or Metastatic, Platinum-resistant Epithelial Ovarian Cancer, Refractory Fallopian Tube Carcinoma, Stage III Colon Cancer, Unresectable or Metastatic Colorectal Cancer, Metastatic pancreatic endocrine carcinoma, Refractory peritoneal cancer, Refractory, metastatic Colorectal carcinoma, Unresectable, metastatic Esophageal Cancer, Unresectable, metastatic Gastric Cancer, Unresectable, metastatic Gastroesophageal Junction Cancer
- Associated Therapies
- Chemotherapy
Comparing Capecitabine and Temozolomide in Combination to Lutetium Lu 177 Dotatate in Patients With Advanced Pancreatic Neuroendocrine Tumors
- First Posted Date
- 2022-02-21
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 198
- Registration Number
- NCT05247905
- Locations
- 🇺🇸
Advocate Outpatient Center - Aurora, Aurora, Illinois, United States
🇺🇸Illinois CancerCare-Kewanee Clinic, Kewanee, Illinois, United States
🇺🇸MU Health Care Goldschmidt Cancer Center, Jefferson City, Missouri, United States
A Study of Ivaltinostat Plus Capecitabine or Capecitabine in Metastatic Pancreatic Adenocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2022-02-21
- Last Posted Date
- 2024-06-04
- Lead Sponsor
- CG Pharmaceuticals, Inc
- Target Recruit Count
- 70
- Registration Number
- NCT05249101
- Locations
- 🇺🇸
Virginia Cancer Specialists, Fairfax, Virginia, United States
🇺🇸The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸HonorHealth Medical Center, Scottsdale, Arizona, United States
SMMART Adaptive Clinical Treatment (ACT) Trial
- Conditions
- Advanced Breast CarcinomaAnatomic Stage IV Breast Cancer AJCC v8Stage II Pancreatic Cancer AJCC v8Stage III Ovarian Cancer AJCC v8Advanced Prostate CarcinomaRecurrent Adult Soft Tissue SarcomaRecurrent Breast CarcinomaStage IV Ovarian Cancer AJCC v8Advanced Malignant Solid NeoplasmAdvanced Ovarian Carcinoma
- Interventions
- Drug: AlectinibDrug: AlpelisibDrug: AnastrozoleBiological: AtezolizumabBiological: BevacizumabProcedure: BiopsyProcedure: Biospecimen CollectionDrug: CapecitabineDrug: CarboplatinDrug: CobimetinibDrug: EntrectinibDrug: EribulinDrug: FulvestrantBiological: Hyaluronidase-zzxf/Pertuzumab/TrastuzumabDrug: IrinotecanDrug: LetrozoleDrug: Nab-paclitaxelDrug: NiraparibDrug: OlaparibDrug: PaclitaxelDrug: PalbociclibBiological: PertuzumabOther: Quality-of-Life AssessmentBiological: TrastuzumabBiological: Trastuzumab EmtansineDrug: VemurafenibDrug: VinorelbineDrug: Vismodegib
- First Posted Date
- 2022-02-14
- Last Posted Date
- 2024-01-23
- Lead Sponsor
- OHSU Knight Cancer Institute
- Registration Number
- NCT05238831
Immunotherapy With Durva and Treme With or Without Capecitabine in Adjuvant Treatment for Biliary Tract Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-02-14
- Last Posted Date
- 2024-01-23
- Target Recruit Count
- 40
- Registration Number
- NCT05239169
- Locations
- 🇩🇪
Krankenhaus Nordwest, Frankfurt am Main, Germany
PACE: PD-1 Antibody For dMMR/MSI-H Stage III Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-02-11
- Last Posted Date
- 2022-12-30
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 323
- Registration Number
- NCT05236972
- Locations
- 🇨🇳
Sun Yat-sen University, Guangzhou, China
Margetuximab Plus Tucatinib and Capecitabine in HER2-positive Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-02-07
- Last Posted Date
- 2022-07-11
- Lead Sponsor
- MedSIR
- Registration Number
- NCT05227131
Preoperative Short-course Radiation Followed by Envafolimab Plus CAPEOX for MSS Locally Advanced Rectal Adenocarcinoma (PRECAM)
- Conditions
- Interventions
- First Posted Date
- 2022-01-31
- Last Posted Date
- 2024-01-29
- Lead Sponsor
- Sir Run Run Shaw Hospital
- Target Recruit Count
- 32
- Registration Number
- NCT05216653
- Locations
- 🇨🇳
Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
Efficacy of Supplement Adjuvant Capecitabine in HR+/HER2- Breast Cancer Patients With High Risks
- First Posted Date
- 2022-01-28
- Last Posted Date
- 2023-04-25
- Target Recruit Count
- 400
- Registration Number
- NCT05212454
- Locations
- 🇨🇳
the Second Affiliated Hospital of Zhejiang Univercity School of Medicine, Hanzhou, Zhejiang, China
Adjuvant Sintilimab Plus Capecitabine in Nasopharyngeal Carcinoma
- First Posted Date
- 2022-01-21
- Last Posted Date
- 2022-05-06
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 150
- Registration Number
- NCT05201859
- Locations
- 🇨🇳
Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Anti-PD-1 and CapOx for the First-line Treatment of dMMR Esophagogastric Cancer (AuspiCiOus)
- Conditions
- Interventions
- First Posted Date
- 2022-01-04
- Last Posted Date
- 2024-08-02
- Target Recruit Count
- 25
- Registration Number
- NCT05177133
- Locations
- 🇳🇱
Amsterdam UMC, location VUmc, Amsterdam, Netherlands
🇳🇱Academic Medical Center, Medical Oncology, Amsterdam, Netherlands
🇳🇱Medisch Centrum Leeuwarden, Leeuwarden, Netherlands
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.